Madrigal Pharmaceuticals Earnings
NASDAQ: MDGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 471.75 0.00%
Next earnings date
Tue, Nov 3, 2026
Fiscal period
Sep/2026
EPS estimate
$1.00
Madrigal Pharmaceuticals earnings summary
Madrigal Pharmaceuticals is scheduled to report Sep/2026 earnings on Nov 3, 2026, with analysts expecting EPS of $1.00. In its most recent report on Jul 30, 2026 (Q2 2026), MDGL posted EPS of $-1.99. Revenue for the quarter was $364.3 million.
Across the last 16 reports, MDGL shares moved an average of 6.9% (in either direction) in the first trading session after results, rising 11 times and falling 5 times.
Summary generated from market data by MetaCap's automated system. Methodology
MDGL earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Jul 30, 2026 | — | $-1.99 | — | +9.1% |
| May 6, 2026 | — | $-3.25 | — | +2.7% |
| Feb 19, 2026 | — | $-2.03 | — | -0.7% |
| Nov 4, 2025 | — | $-4.01 | — | +8.2% |
| Aug 5, 2025 | — | $-1.50 | — | +7.0% |
| May 1, 2025 | — | $-2.61 | — | -6.6% |
| Feb 26, 2025 | — | $2.09 | — | -2.9% |
| Oct 31, 2024 | — | $-4.92 | — | +9.7% |
| Aug 7, 2024 | — | $-7.10 | — | +5.8% |
| May 7, 2024 | — | $-7.38 | — | +7.2% |
| Feb 28, 2024 | — | $-5.68 | — | +1.5% |
| Nov 6, 2023 | — | $-5.34 | — | +27.2% |
| Aug 8, 2023 | — | $-4.69 | — | +4.8% |
| May 9, 2023 | — | $-4.23 | — | -5.6% |
| Feb 23, 2023 | — | $-4.98 | — | -1.4% |
| Nov 3, 2022 | — | $-4.75 | — | +10.6% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.